China macro data suggest ongoing moderate slowing

Over the last week, China’s statistical office has released its macroeconomic data set for August. Indicators came in again mixed with some small positive and negative surprises, but overall the data confirmed the view of an ongoing mild slowing.

Highlights:

  • China’s August macroeconomic data set came in again more mixed, with an overall tendency of a further softening.
  • Especially, urban investment continued to weaken as some ongoing loosening of fiscal policy failed so far to lift infrastructure investment.
  • Export and import growth softened, but overall their levels are still very strong.
  • While last week US President Trump looked ready to impose another round of tariffs on Chinese imports, most recently the US offered new trade talks. We tend to remain sceptical about a positive outcome.

 Download the full publication below.

CHINA MACRO DATA SUGGEST ONGOING MODERATE SLOWING

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.